NCT01437657View on ClinicalTrials.gov

MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

319

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Major Depressive Disorder
Interventions
DRUG

Placebo

Matching RO4917523 placebo orally daily, 6 weeks

DRUG

RO4917523 0.5 mg

0.5 mg orally daily, 6 weeks

DRUG

RO4917523 1.5 mg

1.5 mg orally daily, 6 weeks

Trial Locations (76)

10117

Berlin

11201

Brooklyn

11516

Cedarhurst

12203

Berlin

15213

Pittsburgh

19104

Philadelphia

19139

Philadelphia

19403

Norristown

20127

Aguascalientes

20445

Keelung

21285

Baltimore

30159

Hanover

30328

Atlanta

37000

León

38119

Memphis

40447

Taichung

55131

Mainz

60048

Libertyville

60523

Oak Brook

60563

Naperville

64060

Monterrey

65185

Wiesbaden

71115

Shreveport

72223

Little Rock

73112

Oklahoma City

79104

Freiburg im Breisgau

89102

Las Vegas

92056

Oceanside

92102

San Diego

92103

San Diego

92121

San Diego

92506

Riverside

92595

Wildomar

92626

Costa Mesa

92705

Santa Ana

92845

Garden Grove

92868

Orange

98033

Kirkland

130086

Targouiste

190121

Saint Petersburg

192019

Saint Petersburg

200620

Craiova

540139

Târgu Mureş

900002

Constanța

4781151

Temuco

7500710

Santiago

7580307

Santiago

08053

Marlton

260-8670

Chūōku

060-8648

Hokkaido

659-0093

Hyōgo

216-8511

Kanagawa

252-0303

Kanagawa

114-0024

Kita-ku

682-0023

Kurayoshi-shi

618-8421

Kyoto

569-1041

Osaka

160-8582

Shinjuku-ku

100-0006

Tokyo

107-0052

Tokyo

151-0053

Tokyo

157-8577

Tokyo

162-0821

Tokyo

162-8666

Tokyo

170-0002

Tokyo

187-8551

Tokyo

97-400

Bełchatów

15-464

Bialystok

15-879

Bialystok

16-070

Choroszcz

25-411

Kielce

91-229

Lodz

95-080

Tuszyn

030442

Bucharest

031723

Bucharest

00112

Taipei

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01437657 - MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy | Biotech Hunter | Biotech Hunter